key: cord-0950870-02bkx2x3
authors: Case, James Brett; Chen, Rita E.; Cao, Longxing; Ying, Baoling; Winkler, Emma S.; Johnson, Max; Goreshnik, Inna; Pham, Minh N.; Shrihari, Swathi; Kafai, Natasha M.; Bailey, Adam L.; Xie, Xuping; Shi, Pei-Yong; Ravichandran, Rashmi; Carter, Lauren; Stewart, Lance; Baker, David; Diamond, Michael S.
title: Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease
date: 2021-06-24
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.06.008
sha: e534b6c5df398cced9989989cdf560c92bc9dfdc
doc_id: 950870
cord_uid: 02bkx2x3

Despite the introduction of public health measures and spike protein-based vaccines to mitigate the COVID-19 pandemic, SARS-CoV-2 infections and deaths continue to have a global impact. Previously, we used a structural design approach to develop picomolar range miniproteins targeting the SARS-CoV-2 spike receptor binding domain. Here, we investigated the capacity of modified versions of one lead miniprotein, LCB1, to protect against SARS-CoV-2-mediated lung disease in mice. Systemic administration of LCB1-Fc reduced viral burden, diminished immune cell infiltration and inflammation, and completely prevented lung disease and pathology. A single intranasal dose of LCB1v1.3 reduced SARS-CoV-2 infection in the lung when given as many as five days before or two days after virus inoculation. Importantly, LCB1v1.3 protected in vivo against a historical strain (WA1/2020), an emerging B.1.1.7 strain, and a strain encoding key E484K and N501Y spike protein substitutions. These data support development of LCB1v1.3 for prevention or treatment of SARS-CoV-2 infection.

infectious virus was not recovered from the lungs of LCB1-Fc treated animals collected at either 140 timepoint. Lung sections confirmed that therapy with LCB1-Fc improved pathological outcome 141 (Fig 3G) . At 7 dpi, immune cell infiltrates were absent in the lung sections of LCB1-Fc treated 142 but not control binder-treated animals. Weight loss was absent in LCB1-Fc but not control 143 binder treated animals (Fig 3H) . To evaluate further the therapeutic window of LCB1-Fc, we properties. One concern for biological drugs is their potential immunogenicity, which could limit 183 bioavailability and efficacy. To begin to address this concern, we treated K18-hACE2 transgenic 184 mice with 50 g of control binder or LCB1v1.3 every three days for a total of 18 days (Fig 5A) .

At this time, we collected sera and assessed the presence of anti-LCB1v1.3 antibodies. Only 1 186 of 10 mice developed IgG antibodies against LCB1v1.3 (Fig 5B) . To determine if repeated lung and other organs was observed in all animals receiving LCB1v1.3 (Fig 5D-H neutralizing activity was present in the lungs on day 3 post-administration. In addition, we 203 performed quantitative ELISAs using the same specimens (Fig 5M) , which yielded results 204 consistent with our neutralization activity time-course measurements. Together, these data 205 suggest that the pharmacodynamic and pharmacokinetic half-lives of LCB1v1.3 and LCB1-Fc at 206 key sites of viral replication are sufficient to provide protection for several days after a single 207 dose.

LCB1v1.3 protects against emerging SARS-CoV-2 variants. The emergence of 209 variant strains harboring possible escape mutations is of great concern for antibody-based 210 countermeasures that were designed against historical SARS-CoV-2 spike proteins (Chen et al.,

LCB1v1.3 against the B.1.1.7 and WA1/2020 -E484K/N501Y/D614G strains was approximately 217 45 to 50-fold lower than for the WA1/2020 strain, the EC 50 values still were ~800 pM and 667 218 pM, respectively (Fig S6) . To determine whether LCB1v1.3 could protect in vivo against SARSto inoculation with 10 3 PFU of B.1.1.7 or a recombinant WA1/2020 strain with 222 E484K/N501/D614G mutations. Notably, LCB1v1.3 treatment before challenge with either 223 variant strain protected against weight loss (Fig 6A and 6G ) and viral infection in all tissues 224 collected at 6 dpi (Fig 6B-F and 6H-L) . We also tested the durability of LCB1v1.3 prophylaxis 225 against the WA1/2020-E484K/N501Y/D614G strain when administered by i.n. route. Animals 226 receiving LCB1v1.3 at D-5 or D-3 prior to inoculation with WA1/2020-E484K/N501Y/D614G 227 gained weight (Fig 6M) and had reduced viral RNA levels in the lungs (Fig 6N) compared to 228 control binder-treated animals. Thus, LCB1v1.3 is effective against historical and circulating 229 SARS-CoV-2, as well as strains encoding mutations of concern.

Here, using the stringent K18-hACE2 mouse model of SARS-CoV-2 pathogenesis, we 

In this study, we established the efficacy of two lead candidate miniproteins, LCB1-Fc 301 and LCB1v1.3, against SARS-CoV-2 in K18-hACE2 and 129S2 mice, which have severe and 302 moderate disease phenotypes, respectively. We acknowledge that the therapeutic activity of the 303 miniproteins will need to be corroborated in additional relevant animal models, such as 

Over the past several months, variants of concern have emerged and become leads to morbidity in obese and aged mice and is neutralized by convalescent and post-

Emergence and rapid spread of a new severe 999 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike 1000 mutations in South Africa. medRxiv

A potently neutralizing anti-SARS-CoV-2 antibody 1004 inhibits variants of concern by binding a highly conserved epitope. bioRxiv

501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 infection of human ACE2-transgenic 1027 mice causes severe lung inflammation and impaired function

Human neutralizing antibodies against SARS-CoV-2 require 1031 intact Fc effector functions for optimal therapeutic protection

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and 1035 N501Y variants by BNT162b2 vaccine-elicited sera

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 1043 China: a retrospective cohort study